Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: Results from a real-world cluster-randomized adalimumab trial

Arthritis Care and Research

Volumn 65, Issue 9, 2013, Pages 1401-1409

  Pope, Janet E ^a   Haraoui, Boulos ^b   Rampakakis, Emmanouil ^c   Psaradellis, Eliofotisti ^d   Thorne, Carter ^e   Sampalis, John S ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d JSS Medical Research   (Canada)

^e Southlake Regional Health Care   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CARE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SINGLE BLIND PROCEDURE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLUSTER ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883381190     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22010     Document Type: Article

References (18)

1. Lee DM, Weinblatt ME,. Rheumatoid arthritis. Lancet 2001; 358: 903-11.
2. Pincus T, Callahan LF,. Taking mortality in rheumatoid arthritis seriously: predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986; 13: 841-5.
3. Badley EM, Rasooly I, Webster GK,. Relative importance of musculoskeletal disorders as a cause of chronic health problems, disability, and health care utilization: findings from the 1990 Ontario Health Survey. J Rheumatol 1994; 21: 505-14.
4. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
5. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
6. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40.
7. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-9.
8. Fransen J, Moens HB, Speyer I, van Riel PL,. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005; 64: 1294-8.
9. Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J,. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford) 2010; 49: 2154-64.
10. Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
11. Lerner D, Amick BC III, Rogers WH, Malspeis S, Bungay K, Cynn D,. The Work Limitations Questionnaire. Med Care 2001; 39: 72-85.
12. Hyrich KL, Watson KD, Silman AJ, Symmons DP,. Predictors of response to anti-TNF therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
13. Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years clinical experience. J Rheumatol 2006; 33: 854-61.
14. Barra L, Pope J, Payne M,. Real world anti-TNF treatment in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve HAQ. J Rheumatol 2009; 36: 1421-8.
15. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, on behalf of the Swiss Clinical Quality Management Physicians. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009; 61: 560-8.
16. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL, et al. Concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 583-9.
17. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
18. Zhang J, Shan Y, Reed G, Kremer J, Greenberg J, Baumgartner S, et al. Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large US cohort. Arthritis Care Res (Hoboken) 2011; 63: 1672-9.